Wall Street brokerages forecast that Acer Therapeutics Inc (NASDAQ:ACER) will announce earnings of ($0.48) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Acer Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.55) and the highest estimate coming in at ($0.44). Acer Therapeutics posted earnings per share of ($0.63) in the same quarter last year, which indicates a positive year-over-year growth rate of 23.8%. The business is expected to issue its next earnings results on Wednesday, March 6th.
According to Zacks, analysts expect that Acer Therapeutics will report full year earnings of ($2.12) per share for the current year, with EPS estimates ranging from ($2.29) to ($2.01). For the next financial year, analysts expect that the company will report earnings of ($2.04) per share, with EPS estimates ranging from ($2.93) to ($1.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Acer Therapeutics.
Acer Therapeutics (NASDAQ:ACER) last released its earnings results on Monday, November 12th. The biopharmaceutical company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.10.
Shares of ACER traded up $1.27 during mid-day trading on Friday, reaching $25.37. 14,835 shares of the company’s stock traded hands, compared to its average volume of 28,575. The stock has a market cap of $234.23 million, a price-to-earnings ratio of -6.61 and a beta of 2.75. Acer Therapeutics has a 12 month low of $11.36 and a 12 month high of $34.10.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in shares of Acer Therapeutics by 2,015.8% in the second quarter. BlackRock Inc. now owns 7,786 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 7,418 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Acer Therapeutics by 19,242.2% in the third quarter. JPMorgan Chase & Co. now owns 8,704 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 8,659 shares during the period. First Manhattan Co. boosted its holdings in shares of Acer Therapeutics by 80.0% in the third quarter. First Manhattan Co. now owns 9,000 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 4,000 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Acer Therapeutics in the third quarter valued at approximately $346,000. Finally, Monashee Investment Management LLC purchased a new stake in shares of Acer Therapeutics in the third quarter valued at approximately $350,000. Hedge funds and other institutional investors own 15.97% of the company’s stock.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease.
Further Reading: Understanding Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.